Medical treatment of lung adenosquamous carcinoma
10.3760/cma.j.cn101721-20220325-000087
- VernacularTitle:肺腺鳞癌的内科治疗
- Author:
Cuiyan GUO
1
;
Ligong NIE
Author Information
1. 北京大学第一医院呼吸和危重症医学科，北京 100034
- Keywords:
Adenosquamous carcinoma;
Medical treatment;
Tyrosine kinase inhibitor;
Immunotherapy
- From:
Clinical Medicine of China
2022;38(4):294-297
- CountryChina
- Language:Chinese
-
Abstract:
Adenosquamous carcinoma of the lung is a rare pathological type of non-small cell lung cancer. Adenosquamous carcinoma of the lung has a high degree of malignancy and poor clinical prognosis. Medical treatment plays an important role in patients who have lost the opportunity of operation or have recurrence and metastasis after operation. Platinum based chemotherapy is still the cornerstone of medical treatment. It is recommended that routine driver gene testing should be performed for patients with advanced lung adenosquamous carcinoma. For patients with sensitive driver genes, targeted therapy has a definite effect in some patients. Studies on markers related to immune checkpoint inhibitors suggest that patients with lung adenocarcinoma may benefit from immunotherapy, but there is still a lack of clinical practice data.
